Results 41 to 50 of about 172,248 (309)

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. [PDF]

, 2015
BackgroundPemetrexed is approved in the treatment of advanced stage nonsquamous non-small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify which clinicopathologic characteristics are associated with long-term ...
Liang, Ying, Neal, Joel W, Wakelee, Heather A   +2 more
core   +1 more source

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports

Medicina
Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC).
Kyeong-Min Yeom, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim   +4 more
doaj   +1 more source

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

BMC Cancer, 2011
Background We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment. Methods We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer ...
Fouad Mona N, Weeks Jane C, Zullig Leah L, Kolimaga Jane T, Schrag Deborah, Abbott David H, Grambow Steven C, Malin Jennifer L, Zafar S Yousuf, Ayanian John Z, Wallace Robert, Kahn Katherine L, Ganz Patricia A, Catalano Paul, West Dee W, Provenzale Dawn   +15 more
doaj   +1 more source

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Medicina, 2021
Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab ...
Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Nozomi Tani, Izumi Sato, Mai Tanimura, Takayuki Nakano, Keiko Tanimura, Daishiro Kato, Takayuki Takeda   +9 more
doaj   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study

Clinical Medicine Insights: Oncology
Background: The bevacizumab biosimilar (Encoda), which was approved by the National Medical Products Administration (NMPA) in China in 2019, is a biosimilar of bevacizumab.
Han Shan, Mengmeng Wang, Shuohan Huang, Hongyue Liu, Jiyong Liu, Qiong Du   +5 more
doaj   +1 more source

Combining Bevacizumab with Endostatin Gets Better Antitumor Efficacy in Vivo 
in Lung Cancer Animal Model

Chinese Journal of Lung Cancer, 2013
Background and objective The aim of this study is to investigate difference of antiangiogenesis ablility and interaction about bevacizumab and endostatin in vivo in lung cancer animal model.
Niu NIU, Baolan LI, Chaoyang LIU, Ying HU, Xuebing LI, Jie LI, Heling SHI, Haiqing ZHANG   +7 more
doaj   +1 more source

Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications

American Heart Journal Plus, 2023
Background: Bevacizumab is a humanized monoclonal anti-VEGF antibody often given in combination with fluorouracil-based chemotherapy as therapy for metastatic colorectal cancer (mCRC).
Shinji Rho, Chris Wang, Seyed Hamed Hosseini Dehkordi, James J. Sears, Z. Ian Hu   +4 more
doaj   +1 more source

Deacetylation of ACLY Mediates RNA M6A‐Modification of NOXA and Promotes Chemoresistance of Colorectal Cancer

Advanced Science, EarlyView.
This study investigates the deacetylation of ACLY at K978 acts as a novel risk in colorectal cancer chemoresistance. The deacetylation of K978 induces ACLY relocation to the nucleus and promotes its binding to RBM15, a m6A methylation modification “writer”.
Jun Wen, Mengqin Shen, Haitao Zhao, Liu Liu, Qian Hua, Xiaoping Zhao, Jianjun Liu, Haizhong Feng, Gang Huang   +8 more
wiley   +1 more source

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab

Annals of Gastroenterological Surgery, 2020
Aim The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a
Toshiaki Yoshimoto, Kozo Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, Mitsuo Shimada   +9 more
doaj   +1 more source